Amotiv Limited (TO:AOV) — Market Cap & Net Worth
Market Cap & Net Worth: Amotiv Limited (AOV)
Amotiv Limited (TO:AOV) has a market capitalization of $553.67 Million (CA$765.39 Million) as of May 2, 2026. Listed on the TO stock exchange, this Canada-based company holds position #12003 globally and #343 in its home market, demonstrating a 1.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amotiv Limited's stock price CA$7.55 by its total outstanding shares 101376000 (101.38 Million). Analyse AOV cash flow metrics to see how efficiently the company converts income to cash.
Amotiv Limited Market Cap History: 2015 to 2026
Amotiv Limited's market capitalization history from 2015 to 2026. Data shows growth from $566.14 Million to $553.67 Million (0.20% CAGR).
Amotiv Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amotiv Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.05x
Amotiv Limited's market cap is 1.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
90.40x
Amotiv Limited's market cap is 90.40 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $566.14 Million | $1.04 Million | $34.17 Million | 545.94x | 16.57x |
| 2016 | $787.61 Million | $5.94 Million | $18.56 Million | 132.59x | 42.44x |
| 2017 | $609.40 Million | $8.63 Million | $17.24 Million | 70.58x | 35.34x |
| 2018 | $563.94 Million | $12.50 Million | $24.08 Million | 45.11x | 23.42x |
| 2019 | $555.87 Million | $47.46 Million | $14.52 Million | 11.71x | 38.29x |
| 2020 | $392.34 Million | $199.52 Million | $31.76 Million | 1.97x | 12.35x |
| 2021 | $388.67 Million | $243.48 Million | $15.68 Million | 1.60x | 24.80x |
| 2022 | $379.87 Million | $293.56 Million | -$29.89 Million | 1.29x | N/A |
| 2023 | $380.60 Million | $328.20 Million | -$16.84 Million | 1.16x | N/A |
| 2024 | $391.60 Million | $371.30 Million | $4.33 Million | 1.05x | 90.40x |
Competitor Companies of AOV by Market Capitalization
Companies near Amotiv Limited in the global market cap rankings as of May 2, 2026.
Key companies related to Amotiv Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Amotiv Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Amotiv Limited's market cap moved from $566.14 Million to $ 553.67 Million, with a yearly change of 0.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$553.67 Million | +24.79% |
| 2025 | CA$443.67 Million | +13.30% |
| 2024 | CA$391.60 Million | +2.89% |
| 2023 | CA$380.60 Million | +0.19% |
| 2022 | CA$379.87 Million | -2.26% |
| 2021 | CA$388.67 Million | -0.93% |
| 2020 | CA$392.34 Million | -29.42% |
| 2019 | CA$555.87 Million | -1.43% |
| 2018 | CA$563.94 Million | -7.46% |
| 2017 | CA$609.40 Million | -22.63% |
| 2016 | CA$787.61 Million | +39.12% |
| 2015 | CA$566.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Amotiv Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $553.67 Million USD |
| MoneyControl | $553.67 Million USD |
| MarketWatch | $553.67 Million USD |
| marketcap.company | $553.67 Million USD |
| Reuters | $553.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more